矮身患者的新型致病性NPR2变异以及对rhGH的治疗反应
Hong Chen1,2, Suping Zhang1, Yunteng Sun1
1Endocrinology Department, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, China.
Orphanet journal of rare diseases
|July 27, 2023
概括
这项研究发现了NPR2基因中的新型变异,导致了矮身. 复合人体生长激素 (rhGH) 治疗显示出积极的结果,改善治疗患者的身高.
科学领域:
- 遗传学 遗传学 是一个
- 内分泌学 在内分泌学.
- 骨发育不良症 骨发育不良症
背景情况:
- 在NPR2基因中异构性功能丧失变体是异常性矮身的重要原因.
- 这些变异导致非特异性骨异常,占矮身病例的2-6%.
研究的目的:
- 在中华汉族矮身患者中识别NPR2基因的致病变体.
- 评估这些患者对复合人体生长激素 (rhGH) 的治疗反应.
主要方法:
- 在三个身高矮的患者身上进行了外体序列测序.
- 在体外功能实验,同质模型和分子对接被用来评估变异性病原性.
- 患者接受了两年的rhGH治疗.
主要成果:
- 确定了两个新的异质合体NPR2变体,即c.1579C>T (p.Leu527Phe) 和c.2842dupC (p.His948Profs*5).
- 第三个患者有一种变异导致17号外显子删除和过早停止密码子 (p.His840Gln*).
- 功能性研究显示,变体p.His948Profs*5和p.His840Gln*未能产生cGMP,而p.Leu527Phe显示ATP响应性降低. 经过2年的rhGH治疗,患者的身高增加了1.59个SDS.
结论:
- 确定了两个与矮身相关的新型NPR2变异,扩大了已知的基因型谱.
- rhGH疗法在患有这些NPR2变异的患者的身高改善方面表现出有效性.
更多相关视频
相关概念视频
Nature and Nurture
20.5K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.5K
Gene Therapy
25.5K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.5K


